Compass makes hay in bispecifics
Progress with three bispecific molecules is rewarded with a $120m equity raise.
IO comes agonisingly close to success
Keynote-D18 might have failed on a technicality, but now cash is running out.
Allogene ditches enhanced lymphodepletion
The move comes after a death in the Alpha-3 cema-cel study.
